✨ Check out this trending post from Investopedia | Expert Financial Advice and Markets News 📖
📂 Category: Company News,News
✅ Here’s what you’ll learn:
Key takeaways
- Eli Lilly said Monday it will lower the price of weight-loss drug Zepbound on its LillyDirect platform.
- This move comes about a month after the company announced an agreement with the Trump administration to reduce the costs of weight-loss drugs.
Eli Lilly (LLY) said Monday it will lower the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower the drug’s costs.
The price of a single vial purchased once a month through digital healthcare platform LillyDirect will decrease by $50 for the 2.5-, 7.5-, 10-, 12.5- and 15-milligram doses, and $100 for the 5-milligram dose, the company said. Prices range from $299 for the lowest dose to $449 for the highest dose.
Why is this news important?
Lilly’s decision to reduce Zepbound’s prices comes amid increasing political pressure on the company to make weight-loss medications more accessible to everyone.
The move follows a meeting at the White House in November, where Lilly President and CEO David Rex announced plans to make the company’s weight-loss drugs more affordable and accessible.
As part of the deal, Lilly will make Zepbound and the obesity pill Orforglipron available for as little as $50 a month to Medicare recipients starting next April, pending FDA approval.
In addition, the company agreed that for new medicines, it will follow a “more balanced pricing approach across developed countries.” The Trump administration agreed to grant Lilly a three-year tariff exemption, and it will not be subject to future pricing mandates.
Eli Lilly shares fell about 2% amid broader market losses on Monday, after hitting an all-time high last week. They have added more than a third of their value in 2025.
🔥 Share your opinion below!
#️⃣ #Eli #Lilly #reduces #prices #popular #weightloss #drugs #website #month #Trump #deal
